Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial

BACKGROUND: Recent retrospective data suggest that neoadjuvant androgen deprivation therapy can improve the prognosis of high-risk prostate cancer (PCa) patients. Novel androgen receptor pathway inhibitors are nowadays available for treatment of metastatic PCa and these compounds are promising for e...

Descripción completa

Detalles Bibliográficos
Autores principales: Tosco, Lorenzo, Laenen, Annouschka, Gevaert, Thomas, Salmon, Isabelle, Decaestecker, Christine, Davicioni, Elai, Buerki, Christine, Claessens, Frank, Swinnen, Johan, Goffin, Karolien, Oyen, Raymond, Everaerts, Wouter, Moris, Lisa, De Meerleer, Gert, Haustermans, Karin, Joniau, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879743/
https://www.ncbi.nlm.nih.gov/pubmed/29606109
http://dx.doi.org/10.1186/s12885-018-4275-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879743/
https://www.ncbi.nlm.nih.gov/pubmed/29606109
http://dx.doi.org/10.1186/s12885-018-4275-z

Ejemplares similares